I've been practicing medicine for over two decades. I've sat with women in clinic, on hospital floors, and now through telehealth — and I can tell you that one of the most common moments I witness is this: a woman describes months of fragmented sleep, hot flashes at 2 a.m., anxiety that arrived out of nowhere, a fog that won't lift — and then adds, almost apologetically, "But I'm afraid of hormones." That fear is real, and it didn't come from nowhere. It came from a 2002 study that made headlines around the world and led millions of women to stop — or never start — hormone therapy. What those headlines missed, and what took two more decades of research to fully untangle, is that not all hormones behave the same way in your body. The type matters enormously.

Many women entering perimenopause are told by their clinicians that a single follicle-stimulating hormone (FSH) blood test will determine whether they are in the menopausal transition and whether they are candidates for menopause hormone therapy (MHT). This practice is widespread, but it is not supported by current evidence or by leading menopause guidelines. Understanding why requires a clear look at what FSH is, how it behaves during perimenopause, and what measures actually correlate with both menopausal status and the likelihood of benefit from treatment.

In our last blog, we discussed how the erratic estrogen fluctuations of perimenopause disrupt the production of serotonin and dopamine — two neurotransmitters essential for mood, motivation, sleep, and emotional well-being. The good news is that in addition to hormone therapy, there are evidence-based nutritional supplements that can support your body’s ability to produce these critical brain chemicals.